Clinical Trial

CT-95 in Advanced Cancers Associated With Mesothelin Expression

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with MSLN expression.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2024-12-24; most recent amendment 2026-06-10.
Trial Details
NCT Number NCT06756035
Lead Sponsor Context Therapeutics Inc.
Conditions Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced, Pancreatic Adenocarcinoma Advanced or Metastatic, Lung Adenocarcinoma Metastatic, Cholangiocarcinoma Advanced, Cholangiocarcinoma Non-resectable +3 more
Enrollment 70 participants
Start Date 2025-03-31
Primary Completion 2026-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-12